@Kron00 you raise a good point, is it still in the best interest for the shareholders to do a P2 quick flick. Or is the opportunity now much larger and change in a longer term commercialization strategy needed, for FTO?
How I would like to see things playing out:
(1) EMD AML - Pathway to approval (Partner with Astex) (2) Cardio Protect - P2 (Partner with Janssen J&J / Amgen) (3) FTO? - Partnering required with Pharma but still retain royalty stream to maximise return.
Perhaps the P2 is still ok is deal is structured correctly, happy to let EMD be milestone payments (100 no royalties). Then cardio protect a combo milestone + royalties (80:20), but FTO more leaning to (20:80). Not sure Pharma will pay a great deal of milestone payments relative to FTO royalty potential anyway.
If we take Keyruda as an example, if sold for milestone and approval payments (quick flick) would have been minimal compared to ongoing royalty stream. Have to get the right balance, just some food for thought...
We need EMD AML IP to translate to a commercial deal. Dont see this happening until P2 EML readout and things things should more quickly. But for this we need to recruit patients, this appears to be a bottleneck at the moment.
RAC Price at posting:
$2.20 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)